Company news

Emyria Ltd news

Latest news releases, newest first. Pick a year for every news release, call and deck from that year.

View company

Emyria welcomes dosing of first patient in Phase 3 anxiety trial

January 31, 2023

Appendix 4C - Quarterly

January 30, 2023

First dosing commenced for pivotal EMD-RX5 Phase 3 trial

January 29, 2023

Emyria receives $2.1M R&D tax incentive refund

January 11, 2023

Emyria accepted into National Institutes of Health Program

November 27, 2022

Placement completion and secondary trading notice

November 22, 2022

Emyria completes $3m placement

October 30, 2022

Emyria and UWA expand unique MDMA-inspired analogue library

October 17, 2022

Emyria expands clinical sites for EMD-RX5 Phase 3 trial

September 25, 2022

Emyria commences US preclinical program for MDMA library

September 19, 2022

Appendix 4E and Annual Report

August 29, 2022

Positive results received for Emyrias MDMA-inspired program

August 17, 2022

Emyria receives ethics approval for EMD-RX5 Phase 3 trial

August 16, 2022

Preclinical studies initiated for MDMA-inspired analogues

August 4, 2022

Appendix 4C - Quarterly

July 27, 2022

Emyria expands drug candidate library inspired by MDMA

July 17, 2022

Emyria expands MDMA analogue program with UWA

May 31, 2022

EMD-RX5 demonstrates excellent safety and bioavailability

May 24, 2022

Further positive MDMA analogue screening results received

May 9, 2022

Broker Briefing Presentation

March 24, 2022

Emyria launches second ultra-pure CBD capsule

March 16, 2022

Recruitment commenced for EMD-RX5 Phase 1 Study

March 8, 2022

Ethics approval received for EMD-RX5 Phase 1 Study

March 3, 2022

Emyria grows its novel MDMA-analogue library

February 21, 2022

Application for quotation of securities - EMD

February 13, 2022

Phase 1 trial commences Q1, 2022 for Emyrias ultra-pure CBD

January 19, 2022

Notification regarding unquoted securities - EMD

December 30, 2021

Emyria adds wearables to psychedelic-assisted therapy trials

December 19, 2021

Pause in Trading

December 15, 2021

Positive animal data for Emyrias ultra-pure CBD capsule

December 14, 2021

Positive initial MDMA-analogue screening results

December 7, 2021

Emyria receives $1,162,000 R&D Tax Incentive Refund

November 23, 2021

Emyria Welcomes Tattarang as Strategic Investor

November 21, 2021

MDMA Analogue Development Milestone

October 18, 2021

Emyria selected to join Palantirs Foundry Builders Program

October 6, 2021

Novel MDMA Analogue Screening Program Advanced

September 21, 2021

Emyria Expands Psychiatry Advisory for Psychedelics and MDMA

September 15, 2021

MDMA-analogues Show Promise for Parkinsons Disease

August 31, 2021

Emyria Engages Calvert Labs for Preclinical CBD studies

August 26, 2021

Emyria Appoints Expert Neuropharmacologist for MDMA Program

August 19, 2021

Emyria Executes Pure CBD Agreement with AltaSciences

August 12, 2021

Emyria to Develop Novel Psychedelics Pipeline with UWA

August 4, 2021

Emyria Advances EMD-004 Program Towards Registration

June 14, 2021

Emyria Data Validated, Care Model Reduces Opioids

June 6, 2021

Emyria Obtains TGA Approval for Medical Grade Monitoring App

May 12, 2021

Emyria and MMA launch MDMA-assisted therapy program for PTSD

May 4, 2021

$5m Placement for Drug Registration and Treatment Pipeline

April 21, 2021

Emyria and Cann Partner to Register CBD Product

March 28, 2021

Emyria Adds Second Clinical Site in Perth

March 1, 2021

Emyria adds second Emerald Clinic in Melbourne

February 9, 2021

← Newer news releases · Older news releases →

Decks

The 5 newest of 26 decks. Every deck is listed under its year.